|
|
|
| Effect of Tizanidine on proliferation, migration and opoptosis of U251 cell |
| LIU Bing1 HUO Huiyong1 FENG Shejun1 CAO Ling1 ZHAO Xian1 CAO Yan1 WANG Ruke2 LI Juntao1 |
1.Department of Second Neurology, Handan Central Hospital, Hebei Province, Handan 056000, China;
2.Department of Neurosurgery, Handan Central Hospital, Hebei Province, Handan 056000, China |
|
|
|
Abstract Objective To investigate the effect of Tizanidine on the proliferation, migration and apoptosis of U251, and to explore its mechanism, as well. Methods U251 cells were divided into two groups, one group treated with Tizanidine (20 μmol/L), and the other treated with DMSO as control group. CCK8 assay was used to detect cell proliferation; Transwell assay was performed to detect cell migration and invasion; flow cytometry was adopted to detect cell apoptosis; Western blot was used to detect the expression of PI3K-AKT signaling-related proteins and apoptosis-related proteins. Results The proliferation of U251 cell was inhibited by Tizanidine (P < 0.05); and Tizanidine treatment also inhibited migration and invasion of U251 cell (P < 0.05); Tizanidine induced apoptosis in U251 cell (P < 0.05); Western blot showed that the expression of Bcl-2 was significantly down-regulated (P < 0.05), and the expression of BAX and Active Caspase3 were both significantly up-regulated in Tizanidine-treated U251 cells (P < 0.05), respectively. In addition, Tizanidine significantly inhibited the phosphorylation levels of AKT and mTOR (P < 0.05), and the expression of related downstream proteins (P70s6k and Cyclin D1) were decreased in U251 cells (P < 0.05). Conclusion Tizanidine inhibits proliferation, migration and invasion, induces apoptosis in U251 cell, which may be achieved by inhibiting activation of the PI3K/AKT signaling pathway.
|
|
|
|
|
|
[1] Dwyer CA，Bi WL，Viapiano MS，et al. Brevican knockdown reduces late-stage glioma tumor aggressiveness [J]. J Neurooncol，2014，120（1）：63-72.
[2] Song Y，Luo Q，Long H，et al. Alpha-enolase as a potential cancer prognostic marker promotes cell growth，migration，and invasion in glioma [J]. Mol Cancer，2015，13（1）：235.
[3] Le RE，Taillibert S，Chamberlain MC. Anaplastic glioma：current treatment and management [J]. Expert Rev Neurotherapeutics，2015，15（6）：601-620.
[4] Rd LA，Saper JR. Chronic headache：New advances in treatment strategies[J]. Neurology，2002，59（5 Suppl 2）：S8-S13.
[5] Granfors MT，Backman JT，Laitila J，et al. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro [J]. Br J Clin Pharmacol，2004，57（3）：349-353.
[6] Garside R，Pitt M，Anderson R，et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma：a systematic review and economic evaluation [M]. Health Technol Assess，2007，11（45）：iii-iv，ix-221.
[7] Río-Sancho SD，Merino V，López-Castellano A，et al. A UHPLC-UV Method to Quantify Skin Deposition and Transdermal Permeation of Tizanidine Hydrochloride [J]. J Chromatogr Sci，2016，54（5）：790-795.
[8] Luo J，Manning BD，Cantley LC. Targeting the PI3K-Akt pathway in human cancer：rationale and promise [J]. Cancer Cell，2003，4（4）：257-262.
[9] Vivanco I，Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer [J]. Nat Rev Cancer，2002， 2（7）：489-501.
[10] 程玉，薛晶，次云哲，等.Oct4和PI3K在胃癌组织中的表达变化及意义[J].山东医药，2016，56（34）：27-29.
[11] 张雪群，高卫，潘盼，等.PI3K/AKT及其相关因子在结肠癌中的表达[J].山东大学学报：医学版，2016，54（1）：52-57.
[12] Porta C，Paglino C，Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer [J]. Front Oncol，2014，4（4）：64-68.
[13] Lopiccolo J，Blumenthal GM，Bernstein WB，et al. Targeting the PI3K/Akt/mTOR pathway：effective combinations and clinical considerations [J]. Drug Resist Updat. 2008，11（1）：32-50.
[14] Chang L，Graham PH，Ni J，et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance [J]. Crit Rev Oncol Hematol，2015， 96（3）：507-517.
[15] Yap T，Garrett MM，Raynaud F，et al. Targeting the PI3K-AKT-mTOR pathway：progress，pitfalls，and promises [J]. Curr Opin Pharmacol，2008，8（4）：393-412.
[16] Ben M，Rodrigo D，Josep T. Targeting the PI3K/Akt/mTOR Pathway-Beyond Rapalogs[J]. Oncotarget，2010，1（7）：530-543.
[17] Zhang YH，Zhang J，Song JN，et al. The PI3K-AKT-mTOR pathway activates recovery from general anesthesia [J]. Oncotarget，2016，7（27）：40 939-40 952.
[18] Utermark T，Rao T，Cheng H，et al. The p110{alpha and p110{beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis [J]. Genes Dev，2012，26（14）：1573-1586.
[19] Mabuchi S，Kuroda H，Takahashi R，et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer [J]. Gynecol Oncol，2015，137（1）：173-179.
[20] Li X，Wu C，Chen N，et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma [J]. Oncotarget，2016，7（22）：33 440-33 450. |
|
|
|
